Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors

Seo Hee Choi, Se Hoon Kim, Kyu Won Shim, Jung Woo Han, Junjeong Choi, Dong Seok Kim, Chuhl Joo Lyu, Jun Won Kim, Chang Ok Suh, Jaeho Cho

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


Background To identify prognostic factors and define the optimal management of patients with supratentorial primitive neuroectodermal tumors (sPNETs), we investigated treatment outcomes and explored the prognostic value of specific molecular markers. Methods A total of 47 consecutive patients with pathologically confirmed sPNETs between May 1985 and June 2012 were included. Immunohistochemical analysis of LIN28, OLIG2, and Rad51 expression was performed and correlated with clinical outcome. Results With a median follow-up of 70 months, 5-year overall survival (OS) and progression-free survival (PFS) was 55.5% and 40%, respectively, for all patients. Age, surgical extent, and radiotherapy were significant prognostic factors for OS and PFS. Patients who received initially planned multimodal treatment without interruption (i.e., radiotherapy and surgery (subtotal resection), with or without chemotherapy) showed significantly higher 5-year OS (71.2%) and PFS (63.1%). In 29 patients with available tumor specimens, tumors with high expression of either LIN28 or OLIG2 or elevated level of Rad51 were significantly associated with poorer prognosis. Conclusions We found that multimodal treatment improved outcomes for sPNET patients, especially when radiotherapy and ≥subtotal resection were part of the treatment regimen. Furthermore, we confirmed the prognostic significance of LIN28 and OLIG2 and revealed the potential role of Rad51 in sPNETs.

Original languageEnglish
Article numbere0153443
JournalPloS one
Issue number4
Publication statusPublished - 2016 Apr

Bibliographical note

Publisher Copyright:
© 2016 Choi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors'. Together they form a unique fingerprint.

Cite this